Skip to main content
. 2022 Jun 1;66(6):e00237-22. doi: 10.1128/aac.00237-22

TABLE 1.

Collated PfIVT and counterscreen data for compounds from MMV’s Pathogen Box demonstrating >50% inhibition in a single-point IVT screen at 30 μMa

Compound PfIVT inhibition at 30 μM (%) IC50 value (μM)
PfIVT HsIVT Counterscreen
MMV688407 98.7 6 ± 0.09 5.2 ± 0.02 >30
MMV667494 97.7 0.3 ± 0.09 >30 >30
MMV688991 97.0 0.02 ± 0.008 0.04 ± 0.0003 0.02 ± 0.008
MMV688547 96.7 1.8 ± 0.07 2.7 ± 0.02 >30
MMV687807 95.1 0.09 ± 0.007 0.5 ± 0.006 25 ± 0.8
MMV688362 93.5 2.8 ± 0.08 5.6 ± 0.04 >30
MMV634140 88.4 2.9 ± 0.09 >30 >30
MMV019189 84.4 0.03 ± 0.009 7.7 ± 0.3 7 ± 0.6, (>30)
MMV687243 82.5 2.2 ± 0.08 13 ± 0.2 0.9 ± 0.09
MMV637953 78.7 3.1 ± 0.07 >30 >30
MMV688474 78.4 16 ± 0.9 14 ± 0.07 >30
MMV676008 74.9 0.4 ± 0.08 12 ± 0.4 21 ± 0.6
MMV687730 72.4 3.9 ± 0.8 >30 >30
MMV675998 68.9 13 ± 0.9 18 ± 0.13 >30
MMV688271 65.7 18 ± 0.9 13 ± 0.16 >30
MMV676350 65.1 16 ± 0.8 6.7 ± 0.13 >30
MMV687188 64.9 2.4 ± 0.07 (>30) >30 >30
MMV688372 62.9 0.6 ± 0.06 >30 11 ± 0.8 (>30)
MMV676512 54.2 >30 22 ± 0.46 >30
a

All IC50 values represent the weighted means ± standard deviations of two technical replicates. Compounds with IC50 values 1 order of magnitude (10-fold) higher for the counterscreen than for the PfIVT assay are considered viable hits and are shaded.